Advertisements


"We are going to have lung cancer patients living longer and better:" A new kind of cancer treatment is about to change how we treat the disease (MRK, BMS)

Wikimedia Commons New cancer treatments that harness the body's immune system are ready to go mainstream.  In data presente.....»»

Category: topSource: businessinsiderApr 16th, 2018

Cellectar stock surges 15% premarket after FDA fast tracks treatment for rare childhood cancer

Cellectar Biosciences Inc. said Monday it has received Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for a treatment for a rare kind of cancer in children cal.....»»

Category: topSource: marketwatchSep 17th, 2018

AstraZeneca"s Tagrisso Wins EU Nod for First-Line Lung Cancer

AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) m.....»»

Category: personnelSource: nytJun 11th, 2018

Study finds rare gain for tough-to-treat pancreatic cancer

Patients with pancreatic cancer that hadn't spread lived substantially longer on .....»»

Category: topSource: foxnewsJun 4th, 2018

A cancer treatment that one expert called the "most exciting thing I"ve seen in my lifetime" just got approved to treat more patients (NVS, GILD)

Reuters The FDA just approved a cutting-edge .....»»

Category: topSource: businessinsiderMay 2nd, 2018

Merck’s Bet on Cancer Immunotherapy Is Paying Off in Spades and Helping Lung Cancer Patients Live Longer

A combination of Merck's Keytruda and chemotherapy cut lung cancer death rates in half. New study results released Monday continue to cemen.....»»

Category: europeSource: fortuneApr 16th, 2018

Merck"s Keytruda helps lung cancer patients live longer in trial

(Reuters) - Merck & Co's blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial, potentially cementing its position as the dominant player in the lucrative lung cancer market......»»

Category: topSource: reutersApr 9th, 2018

Merck"s Keytruda meets main goal in pivotal lung cancer trial

(Reuters) - Merck & Co said on Monday a late-stage trial of its blockbuster cancer drug Keytruda met the main goal in helping previously untreated lung cancer patients live longer, sending its shares up 2.6 percent in premarket trade......»»

Category: topSource: reutersApr 9th, 2018

A new type of breast cancer treatment could help stop the spread of a highly aggressive form of the disease

Eric Gaillard/Reut.....»»

Category: topSource: businessinsiderJan 4th, 2019

Amgen small cell lung cancer treatment granted FDA orphan status

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallDec 27th, 2018

Is Spectrum Pharma’s FDA Update Good News for Breast Cancer Patients?

Spectrum Pharma shares dipped on Thursday after the firm announced a key update from the FDA on its treatment of neutropenia in breast cancer patients......»»

Category: blogSource: 247wallstDec 27th, 2018

Merck"s Keytruda Gets FDA Approval for Rare Skin Cancer

Merck (MRK) wins an accelerated approval from the FDA to expand Keytruda's label for the treatment of adult and pediatric patients with r.....»»

Category: smallbizSource: nytDec 20th, 2018

Biotech Stocks Made Big Progress Toward Preventing Heart Attacks in 2018

Key trials suggest doctors may change how they treat patients with cardiovascular disease......»»

Category: topSource: foxnewsDec 18th, 2018

YouTube"s prostate cancer advice may be dangerous, misleading, study finds

Popular YouTube videos on prostate cancer often mislead patients seeking medical screening and treatment information, according to a new study led by researchers at NYU School of Medicine and its... To view the full story, click the title link......»»

Category: blogSource: crainsnewyorkNov 28th, 2018

Bristol-Myers Squibb shares decline on failed lung-cancer drug study

Bristol-Myers Squibb Co. shares declined in the extended session Monday after the drug maker said a lung-cancer treatment.....»»

Category: topSource: marketwatchNov 26th, 2018

Nektar Soars 17% Because It Works Well With Bristol

A trial showed that half the melanoma patients responded to Nektar’s drug when combined with Bristol-Myers Squibb’s cancer treatment Opdivo......»»

Category: topSource: barronsNov 13th, 2018

Why Merrimack Pharma Is Terminating Its Midstage Lung Cancer Study

Merrimack Pharmaceuticals shares dropped early on Friday after the company announced that it would be terminating its midstage SHERLOC study in patients with non-small cell lung cancer......»»

Category: blogSource: 247wallstOct 19th, 2018

Bristol-Myers says trial of small cell lung cancer treatment failed to meet main goal

Bristol-Myers Squibb Co. said Friday a late-stage trial of a treatment for small cell lung cancer failed to meet its main .....»»

Category: topSource: marketwatchOct 12th, 2018

The FDA just approved the second of a new kind of medication that could change the way we treat a condition that affects 39 million Americans (TEVA)

Johan Swanepoel/Shutterstock The FDA on Friday approved a new preventative migraine treatment made by Israeli drugmaker Teva.....»»

Category: topSource: businessinsiderSep 17th, 2018

Cytori treatment of small cell lung cancer granted orphan designation

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 13th, 2018

Sen. John McCain to stop medical treatment, family says

The family of Sen. John McCain said Friday that the Arizona Republican will no longer be treated for the brain cancer he has been battling. "With his usual strength of will, he has now chosen to discontinu.....»»

Category: topSource: marketwatchAug 24th, 2018